Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting OGG1 in Idiopathic Pulmonary Fibrosis

Objective

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies. Approved therapies for IPF have a high rate of discontinuation among patients due to adverse side-effects and present a high unmet need for effective therapies. Oxcia’s OXC-201 is a ground-breaking novel approach for treatment of IPF, based on completely new biology. OXC-201 targets profibrotic and proinflammatory cascades at an early stage on a transcriptional level, and is expected to efficiently prevent lung damage, creating a window for restorative processes to repair scar tissue. OXC-201 has demonstrated significant efficacy in halting disease progression and improved safety and tolerability in preclinical IPF models. In the TOPFIBRO project we will 1) obtain further proof of concept of OXC-201’s efficacy in improving lung function in vivo and confirm antifibrotic efficacy in patient-derived ex vivo models compared to current standard of care, 2) take OXC-201 through preclinical safety assessment studies, 3) fulfill regulatory demands, preparation of IMPD, CTA and ethical applications in order to initiate first-in-human studies, 4) perform first-in-human clinical studies to determine safety profile in healthy volunteers, 5) develop a strong business plan with regulatory, financial and clinical roadmaps to improve investor-readiness. These steps will allow us to further develop OXC-201 with the end goal of bringing it to market via a licensing deal with a large pharmaceutical company. OXC-201 has the potential to fill a large unmet need of the IPF patient community and present the first potentially curative therapy.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-TRANSITION-01

See all projects funded under this call

Coordinator

OXCIA AB
Net EU contribution
€ 2 499 998,75
Address
NORRBACKAGATAN 70 C
113 34 STOCKHOLM
Sweden
SME
Yes
Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 499 998,75